Regulatory

Retatrutide in 2026: new phase 3 data and a closing access window

The strongest weight loss numbers yet landed this year, at the same time a court fight over what retatrutide legally is threatens to end research and compounded access. Here is what the evidence shows and what is actually changing.

SafePeptideUseAugust 20, 20264 min read

Key takeaways

Phase 3 TRIUMPH-1 data presented at the 2026 ADA Scientific Sessions showed average weight loss of about 28 percent at 80 weeks on the top dose, reaching about 30 percent at 104 weeks in the people who stayed on it.
A separate phase 3 trial, TRIUMPH-4, reported large weight loss plus real knee osteoarthritis pain relief, which widens what the drug might eventually be approved for.
The evidence is now strong for weight loss, and the long term safety trial does not report until 2029, so nobody knows yet what years of retatrutide do to the heart and kidneys.
A September 2025 court ruling reopened the question of whether retatrutide is a drug or a biologic. If it is licensed as a biologic, it cannot be legally compounded once approved.
In July 2026 an FDA advisory committee voted on which bulk peptides pharmacies may compound. The direction of travel is toward less access to research and compounded material, not more.

So what actually happened this year?

Two things are happening to retatrutide at once, and they point in opposite directions.

The science got stronger. The first full phase 3 results came out in 2026, and they are the largest weight loss figures any obesity drug has posted. At the same time, the legal ground under the compound started to move. A court reopened the question of what retatrutide even is in the eyes of the law, and the answer decides whether anyone other than Eli Lilly can legally make it.

If you have been watching retatrutide because you might use it someday, this is the year the picture changed. We wrote this to lay out both halves plainly, with sources you can check, and without pretending the safety questions are settled.

How strong is the new trial data?

Retatrutide's pivotal obesity trial, TRIUMPH-1, ran 2,339 adults with obesity on 4, 9, or 12 mg once weekly against placebo. Topline numbers arrived in May 2026, and the fuller results were presented at the 2026 American Diabetes Association Scientific Sessions.

At 80 weeks, average weight loss came in around 19 percent on 4 mg, 26 percent on 9 mg, and 28 percent on 12 mg, against a few percent on placebo. A group who kept going to 104 weeks on the top dose averaged about 30 percent, which works out to roughly 85 pounds off a 268 pound starting weight. Close to half of the top dose group lost at least 30 percent of their body weight, a range that used to belong to bariatric surgery.

One honest caveat on the numbers. How large they look depends on how the trial counts people who stopped early, and the higher figures describe those who stayed on treatment. The detailed results have been presented at a conference, and full peer reviewed publication is still pending, so treat these as strong but not yet final.

Sources:s1, s2

TRIUMPH-4: weight loss and knee pain relief

A second phase 3 trial, TRIUMPH-4, tested retatrutide in 445 adults who had obesity along with knee osteoarthritis. Reported in December 2025, it showed weight loss up to about 29 percent and a large drop in knee pain scores, with roughly one in eight treated people saying they were completely pain free. That result matters because it points at approval in more than one condition, which changes how widely the drug could eventually be prescribed.

Earlier phase 2 work also found lower liver fat in fatty liver disease and better blood sugar in type 2 diabetes. The weight and metabolic story is holding up across trials.

Sources:s3, s4

What is retatrutide, in plain terms?

Retatrutide is a single molecule that switches on three metabolic receptors at once: , , and . The GLP-1 and GIP actions lower appetite and steady blood sugar. The glucagon action nudges up how much energy the body burns. A fatty acid tail lets it stick to a blood protein, which stretches its life out to once weekly dosing.

Some people call it GLP-3. That is a community nickname, not a real receptor. The honest name for what it does is a triple .

For a fuller breakdown of dosing, side effects, and a cautious starting protocol, see our full retatrutide entry.

Sources:s4

Why "drug or biologic" decides who can get it

Warning

Here is the part that controls access. United States law treats a small molecule drug and a biologic differently, and the difference matters for compounding. Approved drugs can, in some situations, be compounded by pharmacies. Biologics licensed under the Public Health Service Act cannot.

The FDA had treated retatrutide as a drug. Lilly argued it should count as a biologic, which carries a much longer market exclusivity. On September 30 2025, the U.S. District Court for the Southern District of Indiana set aside the FDA's reasoning and sent the question back to the agency to define its standard properly. The dispute turns on a technical line: whether retatrutide's 39 amino acid chain, joined to a short second chain, is close enough to a protein to count as a biologic.

Why this reaches you. If retatrutide ends up licensed as a biologic when it is approved, compounded and research versions lose their legal footing entirely. There is no shortage pathway and no bulk substance list for a biologic. Lilly has said it intends to file for approval around the start of 2027, so this is not a distant question.

Sources:s5, s6

The compounding list vote in July

Running alongside the court case, the FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24 2026 to weigh which bulk peptides pharmacies should be allowed to compound. The committee's votes were close, and the broad direction was toward tightening rather than loosening what pharmacies can make.

Stack that on top of the biologic question and the trend is clear. The era of easy research and compounded access to cutting edge metabolic peptides is narrowing while the drugs themselves move toward formal approval.

Sources:s7, s8

What this means if you are following retatrutide

Info

A few honest things to hold together.

The weight loss evidence is now genuinely strong. The long term safety evidence is still thin. The trial built to answer whether retatrutide is safe for the heart and kidneys over years, TRIUMPH-Outcomes, is not expected to finish until 2029. So the current state is that we know it works and we do not yet know what a decade of it does to you.

While it stays unapproved, every research vial is unregulated. What is on the label is not always what is in the vial, and we have seen material sold as retatrutide that was cut with cheaper drugs. If you are going to trust a product, insist on a recent third party Certificate of Analysis with a batch number that matches your vial.

None of this is medical advice. It is a snapshot of a fast moving situation so you can make an informed decision and talk it through with a clinician.

Sources:s9

Sources

[s1]Eli Lilly and Company (2026). Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline, 21 May 2026). manufacturer link
[s2]American Journal of Managed Care (2026). Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial (full data presented at the 2026 ADA Scientific Sessions). rct link
[s3]Patient Care Online (2025). Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial. rct link
[s4]New England Journal of Medicine (2023). Triple Hormone Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial. rct link
[s5]Goodwin (Life Sciences alert) (2025). District Court Sets Aside FDA's Interpretation of "Analogous" to a Protein for Purposes of the "Biological Product" Category (S.D. Indiana, 30 September 2025). regulatory link
[s6]BioSpace (2026). Lilly, FDA retatrutide biologic dispute comes to a head as submission nears. other link
[s7]U.S. FDA (2026). July 23 to 24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. regulatory link
[s8]Partnership for Safe Medicines (2026). FDA peptide panel narrowly votes to add unapproved drugs to compounding list (27 July 2026). other link
[s9]ClinicalTrials.gov (2026). The Effect of Retatrutide Once Weekly on Cardiovascular and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes), NCT06383390, estimated completion February 2029. regulatory link